SLC1A5 and acute myeloid leukemia: Research has shown that by inhibiting IGF2BP2, CWI1-2 can regulate the expression of key targets (such as MYC, GPT2, and SLC1A5) in the glutamine metabolism pathway in an m6A-dependent manner, thereby inhibiting the development of AML and the self-renewal of leukemia stem cells [116].